AZN241122P63000
- 0.07
- 0.000.00%
AstraZeneca Newsroom
AstraZeneca Partner's Orpathys Secures Renewal on China's Drug Reimbursement List
Express News | Astrazeneca appoints new position in oncology business, with Chinese background, expected to become a "bridge" to China.
AstraZeneca's Breast Cancer Drug Wins State Insurance Coverage in China
Express News | Astrazeneca's "breast cancer ADC miracle drug" DS-8201 has been added to the new version of the medical insurance catalog.
AstraZeneca's Strategic Focus and Clinical Trial Success Bolster Buy Rating
Failure of AstraZeneca's AZD4041 a Blow for Non-opioid OUD Treatments
Amgen (AMGN.US) releases mid-term data for weight loss therapy MariTide, with weight loss results comparable to Novartis.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide has achieved significant results in Phase 2 trials.
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
The phase three trial results of the astrazeneca (AZN.US) combination therapy Truqap are positive.
Astrazeneca (AZN.US) today announced positive results from the CAPItello-281 phase 3 clinical trial.
Astrazeneca's Capivasertib successfully met the primary endpoint in Phase III prostate cancer trials. The prospects for Kai Medical-B (2105.HK) AKT inhibitors are bullish.
On November 25, astrazeneca announced that its AKT inhibitor Capivasertib successfully completed the Phase III CAPItello-281 study for the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Following the approval of Capivasertib for breast cancer indications, this study further confirmed the clinical value of the AKT inhibitor. As a drug that shows potential in multiple cancers such as breast cancer, prostate cancer, and ovarian cancer, the market prospects are very broad. In recent years, more and more pharmaceutical companies have begun to pay attention to AKT inhibitors.
AstraZeneca Reports Positive Phase 3 Results for Truqap in Prostate Cancer
AstraZeneca (AZN) Receives a Buy From Goldman Sachs
TRUQAP (Capivasertib) Combination in PTEN-deficient Metastatic Hormone-sensitive Prostate Cancer Demonstrated Statistically Significant and Clinically Meaningful Improvement in Radiographic Progression-free Survival in CAPItello-281 Phase III Trial
GCAR and AstraZeneca Execute Agreement to Evaluate AZD1390 for Glioblastoma
AstraZeneca's Prostate Cancer Treatment Trial Shows Clinically Meaningful Improvement
AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising Demand
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
European Equities Traded in the US as American Depositary Rise in Friday Trading, Up Over 1% for Week
Astrazeneca (AZN.US) and Amgen (AMGN.US) announced the domestic application for the subcutaneous injection of TSLP monoclonal antibody.
CDE's official website shows that astrazeneca (AZN.US) and amgen (AMGN.US) jointly submitted the marketing application for the TSLP monoclonal antibody Tezepelumab injection.